Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326479 | 0.93 | KDR (0.41) | L3MBTL1LMNAKMT2AKDM4EHTT | |
| SCHEMBL4329648 | 0.86 | L3MBTL1 (0.49) | L3MBTL1LMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4330567 | 0.83 | MAPK14 (0.38) | ALDH1A1KDR | |
| SCHEMBL4326460 | 0.80 | KDR (0.42) | L3MBTL1KMT2AALDH1A1KDM4EKDR | |
| SCHEMBL4333183 | 0.80 | CA12 (0.48) | LMNAKMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL14366283 | 0.79 | KDR (0.47) | L3MBTL1LMNAKMT2ASMN1; SMN2CA12 | |
| SCHEMBL4323368 | 0.79 | KDR (0.51) | LMNAKMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL4333756 | 0.72 | MAPT (0.45) | LMNAKMT2AALDH1A1KDM4EHTT | |
| SCHEMBL14366284 | 0.72 | MET (0.48) | MAPTKDR | |
| SCHEMBL4330370 | 0.72 | MAPT (0.48) | LMNAKMT2AHTTMAPTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | L3MBTL1 1054/4885LMNA 4875/4885KMT2A 4095/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | L3MBTL1 1338/4885LMNA 4870/4885KMT2A 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.